NCT00720304 · OUTCOME

Percent of Participants With Local Failure-free Survival

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck · Source last updated 2024-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Participants with Local absence of relapse or recurrence or progression within the prescribed radiation field.

Analysis population: Participants enrolled in study

docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Oral Erlotinib Hydrochloride	43

Source class 1

Values in percent · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Oral Erlotinib Hydrochloride	90	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Participants with Local absence of relapse or recurrence or progression within the prescribed radiation field.

groups

param Type

NUMBER

population Description

Participants enrolled in study

reporting Status

POSTED

time Frame

At 3 years

title

Percent of Participants With Local Failure-free Survival

type

SECONDARY

unit Of Measure

percent

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice